Support Sought for Belantamab Mafodotin Approval in Myeloma Therapy
2025-07-09
PubComNonGov2025-07-09
Carter Struck
WASHINGTON, July 9 -- The U.S. Food and Drug Administration (FDA) received a public comment letter from Robert M. Rifkin, MD, FACP, advocating for the approval of Belantamab Mafodotin in combination w . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
WASHINGTON, July 9 -- The U.S. Food and Drug Administration (FDA) received a public comment letter from Robert M. Rifkin, MD, FACP, advocating for the approval of Belantamab Mafodotin in combination w . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
Copyright © Targeted News Service, 2025